Study of AffloVest in At-Risk Respiratory Patients During COVID-19 Pandemic

Stopped early · Not applicable

Conditions studied: Chronic Obstructive Pulmonary Disease, Chronic Cough, Covid19

In brief

The purpose of the study is to investigate the addition of high frequency chest wall oscillation (HFCWO) therapy to the prescribed care regimen to support the diaphragm during airway clearance among post-COVID patients with COPD and chronic productive cough as a way to limit the advancement of pulmonary symptoms and need for critical services during recovery from COVID-19.

Key facts

Study ID

NCT04654481

Run by

Icahn School of Medicine at Mount Sinai

People needed

1

Starts

2021-07-20

Expected to finish

2021-10-19

Last updated by the study team

2022-05-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult males and females ≥18 years
• Existing diagnosis of COPD for >6 months
• Chronic productive cough
• Radiographic evidence of flattening of the diaphragm
• Prior COVID-19 diagnosis
• Clinically followed by Mount Sinai COVID-19 Post Recovery and Respiratory Institute.
• Ability to provide informed consent
• Ability to read and fill out survey questionnaires via REDCap (surveys will be available in English and Spanish)
• Access to a home computer, tablet, or smartphone

You may not qualify if…

• Presenting with hypoxia (02 sat <90%)
• Acute COVID-19 infection
• Home oxygen dependent
• Established diagnosis of cystic fibrosis
• History of osteoporosis or rib fracture
• Active Hemoptysis
• Pneumothorax

Where it is running

• Mount Sinai Beth Israel — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.